Company profile
Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bexobrutideg | phase3 | — | 6 | active |
| Zelebrudomide | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06593457 | phase1 | completed | 2024-08-20 | 2024-10-29 | Nurix Therapeutics, Inc. | A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects |
| NCT06717269 | phase1 | completed | 2024-11-30 | 2026-05-01 | Nurix Therapeutics, Inc. | A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers |
| NCT05107739 | phase1 | terminated | 2021-12-22 | 2023-05-09 | Nurix Therapeutics, Inc. | A Study of DeTIL-0255 in Adults With Advanced Malignancies |
| NCT05107674 | phase1 | recruiting | 2021-09-29 | 2026-08-31 | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced Malignancies |
| NCT04830137 | phase1 | recruiting | 2021-05-05 | 2026-05-01 | Nurix Therapeutics, Inc. | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies |
FDA applications (0)
No records yet.